MyoKardia Inc (MYOK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
61
About the Report
About the Report
Summary
MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for rare cardiovascular diseases including heritable cardiomyopathies. The company's pipeline products include therapeutic programs for the treatment of heritable cardiomyopathy including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Its lead product candidate, mavacamten, is intended for the treatment of symptomatic oHCM. Its other pipeline product MYK-491 is an orally-administered small molecule to treat genetic DCM caused by mutations in sarcomeric proteins. The company is collaborated with many healthcare organizations for the development and commercialization of product candidates. MyoKardia is headquartered in South San Francisco, California, the US.
MyoKardia Inc (MYOK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
MyoKardia Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MyoKardia Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MyoKardia Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
MyoKardia Raises USD46 Million in Series B Financing 11
MyoKardia Raises USD10 Million in Venture Financing 12
MyoKardia Raises USD 38 Million In Series A Financing 13
Partnerships 14
MyoKardia Enters into Partnership with 23andMe 14
Sanofi Extends its Co-Development Agreement with MyoKardia 15
Equity Offering 16
MyoKardia Raises USD183.7 Million in Public Offering of Shares 16
MyoKardia Raises USD143 Million in Public Offering of Shares 18
Myokardia Plans to Raise up to USD122.2 Million in Public Offering of Shares 20
MyoKardia Raises USD65.6 Million in Public Offering Shares 21
MyoKardia Raises USD62.5 Million in IPO 23
MyoKardia Raises USD5 Million in Private Placement of Series B Redeemable Convertible Preferred Stock 25
MyoKardia Raises USD40 Million in Private Placement of Series B Redeemable Convertible Preferred Stock for USD40.99 Million 26
MyoKardia Raises USD10 Million in Private Placement of Series A-1 Redeemable Convertible Preferred Stock 27
MyoKardia Raises USD6 Million in Private Placement of Preferred Stock 28
MyoKardia Raises USD5 Million in Private Placement of Shares 29
MyoKardia Raises USD8 Million in Private Placement of Preferred Stock 30
MyoKardia Raises USD5.3 Million in Private Placement of Preferred Stock 31
MyoKardia Raises USD5.4 Million in Private Placement of Preferred Stock 32
MyoKardia Raises USD0.04 Million in Private Placement of Shares 33
MyoKardia Raises USD4.6 Million in Private Placement of Preferred Stock 34
MyoKardia Raises USD4 Million in Private Placement of Preferred Stock 35
MyoKardia Inc-Key Competitors 36
MyoKardia Inc-Key Employees 37
MyoKardia Inc-Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 08, 2018: MyoKardia reports second quarter 2018 financial results 39
May 08, 2018: MyoKardia Reports First Quarter 2018 Financial Results 41
Mar 08, 2018: MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results 43
Nov 02, 2017: MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress 45
Aug 07, 2017: MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress 46
Mar 13, 2017: MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress 48
Corporate Communications 50
Apr 04, 2018: MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer 50
Apr 18, 2017: MyoKardia Appoints David Meeker, M.D., to Board of Directors 51
Mar 17, 2017: MyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors 52
Feb 01, 2017: MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs 53
Government and Public Interest 54
Aug 23, 2018: New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation 54
Clinical Trials 56
Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day 56
Oct 30, 2018: MyoKardia shares data on new research program MYK-224 at its 2018 R&D in Day New York City 57
Aug 07, 2017: MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy 58
Other Significant Developments 60
Sep 20, 2018: MyoKardia launches inaugural MyoSeeds research grants program to advance independent research in heart disease 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
List of Figure
List of Figures
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
MyoKardia Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MyoKardia Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MyoKardia Inc, Deals By Therapy Area, 2012 to YTD 2018 9
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MyoKardia Raises USD46 Million in Series B Financing 11
MyoKardia Raises USD10 Million in Venture Financing 12
MyoKardia Raises USD 38 Million In Series A Financing 13
MyoKardia Enters into Partnership with 23andMe 14
Sanofi Extends its Co-Development Agreement with MyoKardia 15
MyoKardia Raises USD183.7 Million in Public Offering of Shares 16
MyoKardia Raises USD143 Million in Public Offering of Shares 18
Myokardia Plans to Raise up to USD122.2 Million in Public Offering of Shares 20
MyoKardia Raises USD65.6 Million in Public Offering Shares 21
MyoKardia Raises USD62.5 Million in IPO 23
MyoKardia Raises USD5 Million in Private Placement of Series B Redeemable Convertible Preferred Stock 25
MyoKardia Raises USD40 Million in Private Placement of Series B Redeemable Convertible Preferred Stock for USD40.99 Million 26
MyoKardia Raises USD10 Million in Private Placement of Series A-1 Redeemable Convertible Preferred Stock 27
MyoKardia Raises USD6 Million in Private Placement of Preferred Stock 28
MyoKardia Raises USD5 Million in Private Placement of Shares 29
MyoKardia Raises USD8 Million in Private Placement of Preferred Stock 30
MyoKardia Raises USD5.3 Million in Private Placement of Preferred Stock 31
MyoKardia Raises USD5.4 Million in Private Placement of Preferred Stock 32
MyoKardia Raises USD0.04 Million in Private Placement of Shares 33
MyoKardia Raises USD4.6 Million in Private Placement of Preferred Stock 34
MyoKardia Raises USD4 Million in Private Placement of Preferred Stock 35
MyoKardia Inc, Key Competitors 36
MyoKardia Inc, Key Employees 37
MyoKardia Inc, Subsidiaries 38
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.